Literature DB >> 24685578

T cell-depleted related HLA-mismatched peripheral blood stem cell transplantation as salvage therapy for graft failure after single unit unrelated donor umbilical cord blood transplantation.

Federico Moscardó1, Samuel Romero2, Jaime Sanz2, Miguel A Sanz2, Pau Montesinos2, Ignacio Lorenzo2, Pilar Solves2, Nelly Carpio2, Guillermo F Sanz2.   

Abstract

Graft failure is a severe treatment complication of unrelated donor umbilical cord blood transplantation (UCBT). Its incidence seems to be higher after UCBT than after transplantation with bone marrow or peripheral blood stem cells (PBSCs). The only curative option is to perform a second transplantation; however, both the ideal stem cell source and the conditioning regimen for this salvage transplantation remain unclear. We report a series of 11 patients who underwent haploidentical PBSC transplantation (PBSCT) as salvage therapy for graft failure after a previous UCBT. The reduced-intensity conditioning regimen consisted of fludarabine 150 mg/m(2) for 3 days and horse antithymocyte globulin 8 mg/kg for 4 days. Ex vivo CD34(+) positive selection was performed in all cases, and no post-transplantation graft-versus-host disease prophylaxis was used. Six of the 9 evaluable patients (67%) eventually engrafted, at a median time of 10 days. The cumulative incidence of engraftment at 28 days was 64% (95% confidence interval [CI], 35% to 92%). Two patients relapsed after PBSCT. The cumulative incidence of TRM was 55% at 2 years (95% CI, 25% to 84%), and the probability of overall survival at 2 years was 36%. Our findings suggest that haploidentical ex vivo T cell-depleted PBSCT is a feasible alternative for treating graft failure after UCBT.
Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cord blood transplant; Graft failure; Haploidentical transplant; T cell depletion

Mesh:

Substances:

Year:  2014        PMID: 24685578     DOI: 10.1016/j.bbmt.2014.03.024

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  7 in total

1.  Non-myeloablative conditioning for second hematopoietic cell transplantation for graft failure in patients with non-malignant disorders: a prospective study and review of the literature.

Authors:  K Mallhi; P J Orchard; W P Miller; Q Cao; J Tolar; T C Lund
Journal:  Bone Marrow Transplant       Date:  2017-01-16       Impact factor: 5.483

2.  Second allogeneic hematopoietic cell transplantation for graft failure: poor outcomes for neutropenic graft failure.

Authors:  Troy C Lund; Jessica Liegel; Nelli Bejanyan; Paul J Orchard; Qing Cao; Jakub Tolar; Claudio Brunstein; John E Wagner; Michael R Verneris; Daniel Weisdorf
Journal:  Am J Hematol       Date:  2015-10       Impact factor: 10.047

3.  Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation.

Authors:  Kaito Harada; Shigeo Fuji; Sachiko Seo; Junya Kanda; Toshimitsu Ueki; Fumihiko Kimura; Koji Kato; Naoyuki Uchida; Kazuhiro Ikegame; Makoto Onizuka; Ken-Ichi Matsuoka; Noriko Doki; Toshiro Kawakita; Yasushi Onishi; Shingo Yano; Takahiro Fukuda; Minoko Takanashi; Yoshinobu Kanda; Yoshiko Atsuta; Masao Ogata
Journal:  Bone Marrow Transplant       Date:  2020-02-12       Impact factor: 5.483

4.  Salvage HLA-haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for graft failure in non-malignant disorders.

Authors:  Michael H Albert; Mehtap Sirin; Manfred Hoenig; Fabian Hauck; Catharina Schuetz; Rajat Bhattacharyya; Polina Stepensky; Elad Jacoby; Tayfun Güngör; Rita Beier; Ansgar Schulz
Journal:  Bone Marrow Transplant       Date:  2021-05-09       Impact factor: 5.483

5.  Graft Failure in Patients With Hematological Malignancies: A Successful Salvage With a Second Transplantation From a Different Haploidentical Donor.

Authors:  Yu-Qian Sun; Yu Wang; Feng-Rong Wang; Chen-Hua Yan; Yi-Fei Cheng; Yu-Hong Chen; Yuan-Yuan Zhang; Ting-Ting Han; Wei Han; Pan Suo; Lan-Ping Xu; Xiao-Hui Zhang; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Front Med (Lausanne)       Date:  2021-06-04

Review 6.  How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?

Authors:  Ying-Jun Chang; Leo Luznik; Ephraim J Fuchs; Xiao-Jun Huang
Journal:  J Hematol Oncol       Date:  2016-04-12       Impact factor: 17.388

7.  Haploidentical hematopoietic stem cell transplantation in a myelofibrosis patient with primary graft failure.

Authors:  Cristina Tecchio; Angelo Andreini; Claudio Costantini; Alberto Zamò; Donata de Sabata; Fiorenza Aprili; Roberta Galavotti; Emanuele Guardalben; Fabio Benedetti
Journal:  Hematol Rep       Date:  2018-01-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.